Biotech News

Encompass Health declares dividend on common stock

Encompass Health Corporation (EHC)Encompass Health CorporationFDA / regulatory

, /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced that its board of directors declared a quarterly cash dividend on its common stock of $0.21 per share, payable on Jan. 15, 2027, to holders of record on Jan. 4, 2027.

About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 178 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from major injuries or illnesses, using advanced technology and innovative treatments to maximize recovery. Encompass Health is recognized by Newsweek as America's Most Awarded Leader in Inpatient Rehabilitation and is ranked among Fortune's World's Most Admired Companies™ and Forbes' America's Best Companies. It is also recognized by Becker's Healthcare and Modern Healthcare as a top healthcare employer. For more information, visit encompasshealth.com and follow us on our newsroom , X , Instagram and Facebook .

From Fortune.© 2026 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health.

Forward-looking statements Statements contained in this press release which are not historical facts, such as the timing and amounts of dividends, are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking statements speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking statements, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, a decision by the board of directors to change the dividend rate in the future; the legal, regulatory and administrative developments that occur at the federal, state and local levels; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; Encompass Health's ability to comply with extensive, complex, and ever-changing regulations in the healthcare industry; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10 ‑ K for the year ended December 31, 202 5, and Form 10-Q for the quarters ended Mar. 31, 2026, and June 30, 2026.

Media contact: Polly Manuel | 205-970-5912 [email protected]

Investor relations contact: Mark Miller | 205-970-5860 [email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/encompass-health-declares-dividend-on-common-stock-302916961.html

SOURCE Encompass Health Corp.

Related news

EHCEncompass Health Corporation2026-11-06 12:30 EST

Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage

HYPRHyperfine2026-11-03 21:05 EST

Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences

ICUSeaStar Medical2026-11-03 13:21 EST

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

VTAKCatheter Precision2026-11-02 13:00 EST

Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

VTAKCatheter Precision2026-10-29 20:15 EST

Flyte Aviation Expands International Operations to Canada

EHCEncompass Health Corporation2026-10-28 20:20 EST

Encompass Health reports results for third quarter 2026

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ICCMIceCure Medical2026-10-20 11:55 EST

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

JNJJohnson & Johnson2026-10-16 10:31 EST

CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

Encompass Health Corporation

Inpatient Rehabilitation Hospitals Encompass Health is the largest U.S. owner and operator of inpatient rehabilitation hospitals. Its national network includes 176 hospitals across 39 states and Puerto Rico. Post-Acute Patient Care The company treats patients recovering from major injuries, illnesses and complex medical events who...

Recent company news

Stock data

Close
141.27 USD
Market cap
10.07B USD
Exchange
NYSE
Sector
Biopharma
Location
United States